Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , and R 4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
1. A compound having the structure of Formula I:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein;
R 1 is selected from the group consisting of
wherein * indicates the carbon atom of the indicated phenyl ring of Formula I to which R 1 is attached;
R 2 is H or 2-hydroxyethoxy;
R 3 is H or methyl; and
R 4 is H or methyl.
2. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomerthereof, wherein R 1 is
3. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 1 is
4. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 1 is
5. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 1 is
6. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 2 is 2-hydroxyethoxy.
7. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 2 is H.
8. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 3 is methyl.
9. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, phaimaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof wherein R 3 is H.
10. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 4 is methyl.
11. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 4 is H.
12. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 2 is H, R 3 is methyl, and R 4 is H.
13. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein R 2 is H, R 3 is H, and R 4 is methyl.
14. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein each of R 2 , R 3 , and R 4 is H.
15. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein each of R 2 is 2-hydroxyethoxy, R 3 is methyl, and R 4 is H.
16. The compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, wherein each of R 2 is 2-hydroxyethoxy, R 3 is H, and R 4 is methyl.
17. The compound of claim 1 , wherein the pharmaceutically acceptable salt or co-crystal is a mesylate salt or co-crystal.
18. The compound of claim 1 , wherein the pharmaceutically acceptable salt or co-crystal is a succinate salt or co-crystal.
19. The compound according to claim 1 , selected from the group consisting of:
2-(5-))6-(6-amino-5-methylpyrazin-2-yl)imidazo [1 ,2-a]pyrazin-8-yl)amino)-2-(4-(oxetan-3-yl)piperazin-1-yl)phenoxy)ethanol;
6-(6-aminopyrazin-2-yl)-N-(4-(4- (oxetan-3-yl)piperazin-1-yl)pheny) imidazo[1,2-a]pyrazin-8-amine;
2-((4-(4-((6-(6-aminopyrazin-2-yl)imidazo[1,2-a]pyrazin-8-yl)amino)phenyl)piperazin-1-yl)methyl)propane-1,3-diol;
2- (5-((6-(6-aminopyrazin-2- yl)imidazo[1 ,2-a]pyrazin-8-yl)amino)-2-(4-(oxetan-3-yl)piperazin- 1-yl)phenoxy)ethanol;
(R)-(4- (4((6-(6-aminopyrazin-2-yl)imidazo[1 ,2- a]pyrazin-8-yl)amino)phenyl)morpholin-2-Yl)methanol;
6-(6-aminopyrazin-2-yl)-5-methyl-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1 ,2-A]pyrazin-8-amine; and
6-(6-amino-5-methylpyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine;
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof.
20. The compound of claim 19 , wherein the pharmaceutically acceptable salt or co-crystal is a mesylate salt or co-crystal.
21. The compound of claim 19 , wherein the pharmaceutically acceptable salt or co-crystal is a succinate salt or co-crystal.
22. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
23. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stercoisomer, mixture of stereoisomers, or tautomer thereof.
24. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
25. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof.
26. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
27. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof.
28. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
29. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof.
30. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
31. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof.
32. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
33. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers, or tautomer thereof.
34. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable vehicle.
35. A compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stercoisomer, mixture of stereoisomers, or tautomer thereof.
36. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the formula:
or a pharmaceutically acceptable salt, pharmaceutically acceptable co-crystal, pharmaceutically acceptable ester, stereoisomer, mixture of stereoisomers or tautomer thereof, and at least one pharmaceutically acceptable vehicle.